Marinus A Blankenstein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7748694/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. JAMA - Journal of the American Medical Association, 2009, 302, 385.	3.8	1,009
2	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.4	354
3	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344
4	Accuracy of 6 Routine 25-Hydroxyvitamin D Assays: Influence of Vitamin D Binding Protein Concentration. Clinical Chemistry, 2012, 58, 543-548.	1.5	320
5	Amyloid-β(1–42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease. Clinical Chemistry, 2010, 56, 248-253.	1.5	301
6	Intrathecal Chemokine Synthesis in Mild Cognitive Impairment and Alzheimer Disease. Archives of Neurology, 2006, 63, 538.	4.9	268
7	The cerebrospinal fluid "Alzheimer profile― Easily said, but what does it mean?. Alzheimer's and Dementia, 2014, 10, 713.	0.4	249
8	Maternal segregation of the Dutch preeclampsia locus at 10q22 with a new member of the winged helix gene family. Nature Genetics, 2005, 37, 514-519.	9.4	206
9	The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Human Reproduction Update, 2014, 20, 76-105.	5.2	206
10	Patients With Alzheimer Disease With Multiple Microbleeds. Stroke, 2009, 40, 3455-3460.	1.0	202
11	Effects of Dietary Phosphate and Calcium Intake on Fibroblast Growth Factor-23. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 383-389.	2.2	187
12	Cerebrospinal fluid AÎ ² 42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimer's and Dementia, 2013, 9, 481-487.	0.4	164
13	Relationship of Cerebrospinal Fluid Markers to ¹¹ C-PiB and ¹⁸ F-FDDNP Binding. Journal of Nuclear Medicine, 2009, 50, 1464-1470.	2.8	162
14	CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiology of Aging, 2007, 28, 1070-1074.	1.5	160
15	A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Annals of Clinical Biochemistry, 2009, 46, 235-240.	0.8	157
16	Concentration of Sex Steroids in Adipose Tissue after Menopause. Steroids, 1998, 63, 319-321.	0.8	156
17	Effects of Processing and Storage Conditions on Amyloid β (1–42) and Tau Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical Practice. Clinical Chemistry, 2005, 51, 189-195.	1.5	151
18	Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clinical Chemistry and Laboratory Medicine, 2011, 49, 353-366.	1.4	140

#	Article	IF	CITATIONS
19	Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiology of Aging, 2009, 30, 1885-1889.	1.5	135
20	Aromatase and COX-2 expression in human breast cancers. Journal of Steroid Biochemistry and Molecular Biology, 2001, 79, 41-47.	1.2	131
21	Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents. Bone, 2017, 95, 11-19.	1.4	127
22	Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology, 2013, 81, 1409-1416.	1.5	122
23	CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiology of Aging, 2009, 30, 1895-1901.	1.5	121
24	The parent-of-origin effect of 10q22 in pre-eclamptic females coincides with two regions clustered for genes with down-regulated expression in androgenetic placentas. Molecular Human Reproduction, 2004, 10, 589-598.	1.3	116
25	Amyloid β 38, 40, and 42 species in cerebrospinal fluid: More of the same?. Annals of Neurology, 2005, 58, 139-142.	2.8	112
26	CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiology of Aging, 2008, 29, 669-675.	1.5	103
27	Dynamics of serum testosterone during the menstrual cycle evaluated by daily measurements with an ID-LC–MS/MS method and a 2nd generation automated immunoassay. Steroids, 2013, 78, 96-101.	0.8	102
28	Basal follicle-stimulating hormone levels are of limited value in predicting ongoing pregnancy rates after in vitro fertilization. Fertility and Sterility, 2000, 73, 552-557.	0.5	97
29	Genetics of preeclampsia: paradigm shifts. Human Genetics, 2007, 120, 607-612.	1.8	91
30	Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study. Neurobiology of Aging, 2010, 31, 758-764.	1.5	90
31	Effect of mechanical loading on insulin-like growth factor-I gene expression in rat tibia. Journal of Endocrinology, 2007, 192, 131-140.	1.2	87
32	CSF α-Synuclein Does Not Discriminate Dementia with Lewy Bodies from Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 87-95.	1.2	87
33	Neurofilament ELISA validation. Journal of Immunological Methods, 2010, 352, 23-31.	0.6	86
34	Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP. Prostate, 1993, 23, 213-223.	1.2	83
35	The effect of amyloid associated proteins on the expression of genes involved in amyloid-β clearance by adult human astrocytes. Experimental Neurology, 2012, 233, 373-379.	2.0	81
36	Serum sarcosine is not a marker for prostate cancer. Annals of Clinical Biochemistry, 2010, 47, 282-282.	0.8	78

MARINUS A BLANKENSTEIN

#	Article	IF	CITATIONS
37	Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42. Biomarkers in Medicine, 2012, 6, 409-417.	0.6	76
38	BACE1 Activity in Cerebrospinal Fluid and Its Relation to Markers of AD Pathology. Journal of Alzheimer's Disease, 2010, 20, 253-260.	1.2	75
39	Laboratory aspects of circulating Â-Klotho. Nephrology Dialysis Transplantation, 2013, 28, 2283-2287.	0.4	75
40	Injury Markers but not Amyloid Markers are Associated with Rapid Progression from Mild Cognitive Impairment to Dementia in Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 29, 319-327.	1.2	73
41	Apolipoproteins E and J interfere with amyloidâ€beta uptake by primary human astrocytes and microglia <i>in vitro</i> . Glia, 2014, 62, 493-503.	2.5	71
42	The STOX1 genotype associated with pre-eclampsia leads to a reduction of trophoblast invasion by α-T-catenin upregulation. Human Molecular Genetics, 2010, 19, 2658-2667.	1.4	70
43	Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals. Scandinavian Journal of Gastroenterology, 2011, 46, 60-69.	0.6	70
44	CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Multiple Sclerosis Journal, 2013, 19, 436-442.	1.4	70
45	Detection of Chromosome 21-encoded mRNA of Placental Origin in Maternal Plasma. Clinical Chemistry, 2003, 49, 1445-1449.	1.5	68
46	Determination of fibroblast growth factor 23. Annals of Clinical Biochemistry, 2009, 46, 338-340.	0.8	67
47	LHRH-Agonist treatment in clinical and experimental human breast cancer. The Journal of Steroid Biochemistry, 1985, 23, 867-873.	1.3	66
48	Comparison of 6 Automated Assays for Total and Free Prostate-Specific Antigen with Special Reference to Their Reactivity toward the WHO 96/670 Reference Preparation. Clinical Chemistry, 2006, 52, 1568-1574.	1.5	66
49	Comparison of 7 Published LC-MS/MS Methods for the Simultaneous Measurement of Testosterone, Androstenedione, and Dehydroepiandrosterone in Serum. Clinical Chemistry, 2015, 61, 1475-1483.	1.5	64
50	Markers for Presymptomatic Prediction of Preeclampsia and Intrauterine Growth Restriction. Hypertension in Pregnancy, 2004, 23, 171-189.	0.5	61
51	Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. European Journal of Cancer & Clinical Oncology, 1985, 21, 1493-1499.	0.9	60
52	Intratumoral levels of estrogens in breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 1999, 69, 293-297.	1.2	60
53	Endogenous oestrogens and androgens in normal and malignant endometrial and mammary tissues. European Journal of Cancer & Clinical Oncology, 1989, 25, 1953-1959.	0.9	59
54	Reproducibility and reliability of repeated semen analyses in male partners of subfertile couples. Fertility and Sterility, 2010, 94, 2631-2635.	0.5	59

#	Article	IF	CITATIONS
55	The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA. Journal of Immunological Methods, 2014, 402, 43-49.	0.6	57
56	Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: A randomized placebo-controlled study. American Journal of Obstetrics and Gynecology, 2003, 189, 1221-1227.	0.7	56
57	Vitamin D supplementation and testosterone concentrations in male human subjects. Clinical Endocrinology, 2015, 83, 105-110.	1.2	56
58	Microbleeds relate to altered amyloid-beta metabolism in Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1011.e1-1011.e9.	1.5	55
59	Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 46, 1103-1110.	1.2	55
60	Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. Neurobiology of Aging, 2012, 33, 1591-1598.	1.5	52
61	N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. Journal of Neurology, 2014, 261, 2338-2343.	1.8	52
62	Amyloid-β Oligomers Relate to Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 35-43.	1.2	52
63	Endogenous steroid hormones and local aromatase activity in the breast. Journal of Steroid Biochemistry and Molecular Biology, 1991, 39, 799-804. Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid <mml:math< td=""><td>1.2</td><td>51</td></mml:math<>	1.2	51
64	xmlns:mml="http://www.w3.org/1998/Math/MathML"> <mml:mrow><mml:msub><mml:mi>l²</mml:mi><mml:r< td=""><td>row><mn 1.1</mn </td><td>nl:mrow><mr 50</mr </td></mml:r<></mml:msub></mml:mrow>	row> <mn 1.1</mn 	nl:mrow> <mr 50</mr
	Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop.		
65	Decreased plasma levels of metastin in early pregnancy are associated with small for gestational age neonates. Prenatal Diagnosis, 2008, 28, 299-303.	1.1	49
66	Ki-67 and p53 in T2 laryngeal cancer. Laryngoscope, 1998, 108, 1548-1552.	1.1	48
67	New Research Criteria for the Diagnosis of Alzheimer's Disease Applied in a Memory Clinic Population. Dementia and Geriatric Cognitive Disorders, 2010, 30, 1-7.	0.7	48
68	Serum testosterone levels measured by isotope dilution-liquid chromatography–tandem mass spectrometry in postmenopausal women versus those in women who underwent bilateral oophorectomy. Annals of Clinical Biochemistry, 2010, 47, 248-252.	0.8	48
69	Proximal Fluid Proteome Profiling of Mouse Colon Tumors Reveals Biomarkers for Early Diagnosis of Human Colorectal Cancer. Clinical Cancer Research, 2012, 18, 2613-2624.	3.2	46
70	BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer's disease. Neurobiology of Aging, 2014, 35, 1596-1604.	1.5	46
71	CSF Biomarkers in Alzheimer's Disease and Controls: Associations with APOE Genotype are Modified by Age. Journal of Alzheimer's Disease, 2009, 16, 601-607.	1.2	45
72	Testosterone, free testosterone, and free androgen index in women: Reference intervals, biological variation, and diagnostic value in polycystic ovary syndrome. Clinica Chimica Acta, 2015, 450, 227-232.	0.5	45

#	Article	IF	CITATIONS
73	Expression of different phenotypes in cell lines from canine mammary spindle-cell tumours and osteosarcomas indicating a pluripotent mammary stem cell origin. Breast Cancer Research and Treatment, 2000, 61, 197-210.	1.1	44
74	EEG abnormalities in early and late onset Alzheimer's disease: understanding heterogeneity. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 67-71.	0.9	42
75	Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer. Breast Cancer Research and Treatment, 1984, 4, 209-220.	1.1	41
76	The Pre-Eclampsia Gene STOX1 Controls a Conserved Pathway in Placenta and Brain Upregulated in Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 19, 673-679.	1.2	40
77	Additional Value of CSF Amyloid-β40 Levels in the Differentiation between FTLD and Control Subjects. Journal of Alzheimer's Disease, 2010, 20, 445-452.	1.2	39
78	Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer. BJU International, 2012, 109, 176-182.	1.3	39
79	Visceral Adipose Tissue Is Associated with Circulating High Affinity Growth Hormone-Binding Protein. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 760-764.	1.8	38
80	Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic. Dementia and Geriatric Cognitive Disorders, 2010, 29, 491-497.	0.7	38
81	Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. Methods, 2012, 56, 508-513.	1.9	38
82	Comparison of eight routine unpublished LC–MS/MS methods for the simultaneous measurement of testosterone and androstenedione in serum. Clinica Chimica Acta, 2016, 454, 112-118.	0.5	38
83	Simultaneous measurement of testosterone, androstenedione and dehydroepiandrosterone (DHEA) in serum and plasma using Isotope-Dilution 2-Dimension Ultra High Performance Liquid-Chromatography Tandem Mass Spectrometry (ID-LC–MS/MS). Clinica Chimica Acta, 2015, 438, 157-159.	0.5	37
84	Determination of human reference values for serum total 1,25-dihydroxyvitamin D using an extensively validated 2D ID-UPLC–MS/MS method. Journal of Steroid Biochemistry and Molecular Biology, 2016, 164, 127-133.	1.2	37
85	Combined effects of Buserelin, estradiol and Tamoxifen on the growth of MCF-7 human breast cancer cells in vitro. Biochemical and Biophysical Research Communications, 1986, 140, 550-556.	1.0	36
86	Estrogens in tissues: Uptake from the peripheral circulation or local production. Steroids, 1987, 50, 297-306.	0.8	35
87	Distribution of APOE Genotypes in a Memory Clinic Cohort. Dementia and Geriatric Cognitive Disorders, 2008, 25, 433-438.	0.7	35
88	Analysis of glucagon-like peptide 1; what to measure?. Clinica Chimica Acta, 2011, 412, 1191-1194.	0.5	34
89	Testosterone, androstenedione, cortisol and cortisone levels in human unstimulated, stimulated and parotid saliva. Steroids, 2018, 138, 26-34.	0.8	34
90	Metabolism of estradiol by human breast cancer. European Journal of Cancer & Clinical Oncology, 1988, 24, 1171-1178.	0.9	31

MARINUS A BLANKENSTEIN

#	Article	IF	CITATIONS
91	Importance of local aromatase activity in hormone-dependent breast cancer: a review. Breast, 2001, 10, 91-99.	0.9	31
92	Joint Effect of Hypertension and APOE Genotype on CSF Biomarkers for Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, 1083-1090.	1.2	30
93	Speculation on the mechanism of action of triphenylethylene antioestrogens. Biochemical Pharmacology, 1994, 47, 1927-1937.	2.0	29
94	Serum CA-125 in Relation to Adnexal Dysplasia and Cancer in Women at Hereditary High Risk of Ovarian Cancer. Journal of Clinical Oncology, 2007, 25, 1383-1389.	0.8	29
95	Serum Amyloid P Component as a Biomarker in Mild Cognitive Impairment and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2008, 26, 522-527.	0.7	27
96	Influence of blood collection in plastic vs. glass evacuated serum-separator tubes on hormone and tumour marker levels. Clinical Chemistry and Laboratory Medicine, 2004, 42, 435-9.	1.4	26
97	Differential downregulation of αT-catenin expression in placenta: trophoblast cell type-dependent imprinting of the CTNNA3 gene. Gene Expression Patterns, 2004, 5, 61-65.	0.3	26
98	EEG functional connectivity and ApoE genotype in Alzheimer's disease and controls. Clinical Neurophysiology, 2008, 119, 2727-2732.	0.7	26
99	Dementia Mimicking Alzheimer's Disease Owing to a Tau Mutation: CSF and PET Findings. Alzheimer Disease and Associated Disorders, 2010, 24, 303-307.	0.6	26
100	44 Single-Nucleotide Polymorphisms Expressed by Placental RNA: Assessment for Use in Noninvasive Prenatal Diagnosis of Trisomy 21. Clinical Chemistry, 2007, 53, 2223-2224.	1.5	25
101	Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer. BJU International, 2012, 109, 183-188.	1.3	25
102	Measurement of dehydroepiandrosterone sulphate (DHEAS): A comparison of Isotope-Dilution Liquid Chromatography Tandem Mass Spectrometry (ID-LC-MS/MS) and seven currently available immunoassays. Clinica Chimica Acta, 2013, 424, 22-26.	0.5	25
103	Discriminatory and predictive capabilities of enzymeâ€linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. Alzheimer's and Dementia, 2013, 9, 276-283.	0.4	25
104	Detection of Placental Transcription Factor mRNA in Maternal Plasma. Clinical Chemistry, 2004, 50, 1413-1414.	1.5	24
105	Facilitating the Validation of Novel Protein Biomarkers for Dementia: An Optimal Workflow for the Development of Sandwich Immunoassays. Frontiers in Neurology, 2015, 6, 202.	1.1	24
106	The neurofilament light chain is not stable in vitro. Annals of Neurology, 2011, 69, 1065-1066.	2.8	23
107	H9c2 cardiomyoblasts produce thyroid hormone. American Journal of Physiology - Cell Physiology, 2008, 294, C1227-C1233.	2.1	22
108	A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2013, 9, 262-268.	0.4	22

#	Article	IF	CITATIONS
109	Reference values for salivary testosterone in adolescent boys and girls determined using Isotope-Dilution Liquid-Chromatography Tandem Mass Spectrometry (ID-LC–MS/MS). Clinica Chimica Acta, 2016, 456, 15-18.	0.5	22
110	Quantification of amyloid-beta 40 in cerebrospinal fluid. Journal of Immunological Methods, 2009, 348, 57-66.	0.6	21
111	Evaluation of Intrathecal Serum Amyloid P (SAP) and C-Reactive Protein (CRP) Synthesis in Alzheimer's Disease with the Use of Index Values. Journal of Alzheimer's Disease, 2011, 22, 1073-1079.	1.2	21
112	Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples. Clinical Chemistry and Laboratory Medicine, 2012, 50, 61-5.	1.4	21
113	α-Klotho is unstable in human urine. Kidney International, 2015, 88, 1442-1444.	2.6	21
114	Radioresistance and p53 status of T2 laryngeal carcinoma: Analysis by immunohistochemistry and denaturing gradient gel electrophoresis. , 1996, 78, 991-997.		20
115	Effect of Raloxifene Treatment on Osteocyte Apoptosis in Postmenopausal Women. Calcified Tissue International, 2007, 81, 183-190.	1.5	20
116	A Combination of Serum Tumor Markers Identifies High-Risk Patients with Early-Stage Squamous Cervical Cancer. Tumor Biology, 2008, 29, 9-17.	0.8	20
117	Determination of cortisol and cortisone in human mother's milk. Clinica Chimica Acta, 2015, 444, 154-155.	0.5	20
118	Two cases of antiruthenium antibody interference in Modular free thyroxine assay. Annals of Clinical Biochemistry, 2009, 46, 263-264.	0.8	19
119	Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiology of Aging, 2010, 31, 539-540.	1.5	19
120	Alzheimer's disease patients not carrying the apolipoprotein E Îμ4 allele show more severe slowing of oscillatory brain activity. Neurobiology of Aging, 2013, 34, 2158-2163.	1.5	19
121	Prevalence of vitamin D deficiency and consequences for PTH reference values. Clinica Chimica Acta, 2013, 426, 41-45.	0.5	19
122	Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia. , 2013, 9, 269-275.		19
123	Salivary testosterone in female-to-male transgender adolescents during treatment with intra-muscular injectable testosterone esters. Steroids, 2013, 78, 91-95.	0.8	19
124	Increase in Cerebrospinal Fluid F2-Isoprostanes is Related to Cognitive Decline in APOE ε4 Carriers. Journal of Alzheimer's Disease, 2013, 36, 563-570.	1.2	19
125	Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 139-146.	1.2	19
126	LHRH-agonist treatment in metastatic prostate carcinoma. European Journal of Cancer & Clinical Oncology, 1984, 20, 483-493.	0.9	18

#	Article	IF	CITATIONS
127	Comparative affinity of steroidal and non-steroidal antioestrogens, cholesterol derivatives and compounds with a dialkylamino side chain for the rat liver antioestrogen binding site. Biochemical Pharmacology, 1992, 43, 2511-2518.	2.0	18
128	Performance of firstâ€ŧrimester combined test for Down syndrome in different maternal age groups: reason for adjustments in screening policy?. Prenatal Diagnosis, 2011, 31, 1241-1245.	1.1	18
129	Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid Î ² -peptide. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 179-187.	1.4	18
130	Evaluation of the introduction of the national Down syndrome screening program in the Netherlands: age-related uptake of prenatal screening and invasive diagnostic testing. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 174, 59-63.	0.5	17
131	Comparison of multiplex platforms for cytokine assessments and their potential use for biomarker profiling in multiple sclerosis. Cytokine, 2017, 91, 145-152.	1.4	17
132	Usefulness of Longitudinal Measurements of β-Amyloid1–42 in Cerebrospinal Fluid of Patients with Various Cognitive and Neurologic Disorders. Clinical Chemistry, 2006, 52, 1604-1606.	1.5	16
133	Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1300-4.	1.4	16
134	Increased Expression of Matrix Extracellular Phosphoglycoprotein (MEPE) in Cortical Bone of the Rat Tibia after Mechanical Loading: Identification by Oligonucleotide Microarray. PLoS ONE, 2013, 8, e79672.	1.1	15
135	A Novel Method to Identify Syncytiotrophoblast-Derived RNA Products Representative of Trisomy 21 Placental RNA in Maternal Plasma. Methods in Molecular Biology, 2008, 444, 291-302.	0.4	15
136	The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease. Journal of Steroid Biochemistry and Molecular Biology, 2003, 87, 149-155.	1.2	13
137	Reply to "STOX1 is not imprinted and is not likely to be involved in preeclampsia― Nature Genetics, 2007, 39, 280-281.	9.4	13
138	Estimation of total oestrogen receptors in DMBA-induced rat mammary tumors by exchange of nuclear bound ligand at low temperature; A comparison with rat uterus. The Journal of Steroid Biochemistry, 1980, 13, 557-564.	1.3	12
139	Nuclear androgen receptors in human prostatic tissue. Extraction with heparin and estimation of the number of binding sites with different methods. Clinica Chimica Acta, 1981, 109, 91-102.	0.5	12
140	Plasma hepatocyte growth factor as a marker for small-for-gestational age fetuses. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2003, 110, 20-25.	0.5	12
141	Progression from MCI to AD: Predictive value of CSF Al̂ ² 42 is modified by APOE genotype. Neurobiology of Aging, 2011, 32, 1372-1378.	1.5	12
142	Quantification of clusterin in paired cerebrospinal fluid and plasma samples. Annals of Clinical Biochemistry, 2014, 51, 557-567.	0.8	12
143	Inaccurate First-Generation Testosterone Assays Are Influenced by Sex Hormone–Binding Globulin Concentrations. journal of applied laboratory medicine, The, 2016, 1, 194-201.	0.6	12
144	Biologically active human islet amyloid polypeptide/amylin in transgenic mice. European Journal of Endocrinology, 1997, 136, 107-113.	1.9	11

#	Article	IF	CITATIONS
145	Islet amyloid polypeptide/amylin messenger RNA and protein expression in human insulinomas in relation to amyloid formation. European Journal of Endocrinology, 1999, 140, 69-78.	1.9	10
146	ASSOCIATION BETWEEN VITAMIN B6 AND WHITE MATTER HYPERINTENSITIES IN PATIENTS WITH ALZHEIMER'S DISEASE NOT MEDIATED BY HOMOCYSTEINE METABOLISM. Journal of the American Geriatrics Society, 2007, 55, 956-958.	1.3	10
147	Performance of free β-human chorionic gonadotrophin (free β-hCG) and pregnancy associated plasma protein-A (PAPP-A) analysis between Delfia Xpress and AutoDelfia systems in The Netherlands. Clinical Chemistry and Laboratory Medicine, 2009, 47, 222-6.	1.4	10
148	ADAM12s and PP13 as first trimester screening markers for adverse pregnancy outcome. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1279-1284.	1.4	10
149	None of Four Commercially Available Assays Detects Prolactin in Human Saliva. Clinical Chemistry, 2000, 46, 1409-1410.	1.5	9
150	Differences and Similarities between Two Frequently Used Assays for Amyloid β 42 in Cerebrospinal Fluid. Clinical Chemistry, 2005, 51, 1057-1060.	1.5	9
151	CSF levels of PSA and PSA–ACT complexes in Alzheimer's disease. Annals of Clinical Biochemistry, 2009, 46, 477-483.	0.8	9
152	Measurement of Allelic-Expression Ratios in Trisomy 21 Placentas by Quencher Extension of Heterozygous Samples Identified by Partially Denaturing HPLC. Clinical Chemistry, 2008, 54, 437-440.	1.5	8
153	Differential effect of gonadotropin-releasing hormone analogue treatment on estrogen levels and sulfatase activity in uterine leiomyoma and myometrium. Fertility and Sterility, 2002, 77, 1227-1232.	0.5	7
154	Interference in human chorionic gonadotropin (hCG) analysis by macro-hCG. Clinica Chimica Acta, 2011, 412, 2349-2350.	0.5	7
155	Improvement and Multicenter Evaluation of the Analytical Performance of an Automated Chemiluminescent Immunoassay for Alpha Fetoprotein. International Journal of Biological Markers, 2012, 27, 39-46.	0.7	7
156	Peculiar observations in measuring testosterone in women treated with oral contraceptives supplemented with dehydroepiandrosterone (DHEA). Clinica Chimica Acta, 2014, 430, 92-95.	0.5	7
157	Measurement of dehydroepiandrosterone sulfate (DHEAS) in serum and cerebrospinal fluid by isotope-dilution liquid chromatography tandem mass spectrometry. Clinica Chimica Acta, 2012, 414, 246-247.	0.5	6
158	Neurokinin B levels in maternal circulation during early pregnancy. Clinical Chemistry and Laboratory Medicine, 2004, 42, 611-3.	1.4	5
159	Measuring salivary cortisol with the Architect i2000 random access analyser. Annals of Clinical Biochemistry, 2009, 46, 261-262.	0.8	5
160	Meningioma in untreated congenital adrenal hyperplasia: a relationship?. Journal of Neuro-Oncology, 2009, 92, 223-225.	1.4	5
161	Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration. Journal of Neuroscience Methods, 2010, 193, 296-299.	1.3	5
162	Reference intervals – ever met a normal person?. Annals of Clinical Biochemistry, 2015, 52, 5-6.	0.8	5

#	Article	IF	CITATIONS
163	Biodistribution of 123I-Labeled 4-hydroxytamoxifen derivatives in rats with dimethylbenzanthracene-induced mammary carcinomas. Nuclear Medicine and Biology, 1997, 24, 719-722.	0.3	4
164	Cystatin C Can Be Measured Reliably in Capillary Blood Samples. Clinical Chemistry, 2005, 51, 903-904.	1.5	4
165	Isotopically labelled testosterone derivatives as internal standards in liquid chromatography-tandem mass spectrometry. Annals of Clinical Biochemistry, 2013, 50, 275-276.	0.8	4
166	First-Trimester Screening for Down Syndrome with Serum Sampling at Different Gestational Ages: The Effect on Screening Performance. Fetal Diagnosis and Therapy, 2014, 36, 293-298.	0.6	4
167	Importance of sample size in hospital point-of-care glucose measurements. Clinical Chemistry and Laboratory Medicine, 2008, 46, 874-5.	1.4	2
168	Intralipid causes falsely increased glucose concentrations with the Hemocue glucose analyzer. Clinical Chemistry and Laboratory Medicine, 2010, 48, 737-8.	1.4	2
169	Processing effects and storage conditions on A Disintegrin And Metalloprotease (ADAM12s), a maternal serum marker for adverse pregnancy outcome. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1579-81.	1.4	1
170	P3-031: AMYLOID-BETA DEGRADATION BY HUMAN ASTROCYTES IS IMPAIRED BY APOJ AND APOE. , 2014, 10, P638-P638.		1
171	Inflammatory markers in AD and MCI patients with different biomarker profiles—interpretation of serum and CSF levels. Neurobiology of Aging, 2010, 31, 1655.	1.5	0
172	O1-09-01: Diagnostic impact of CSF biomarkers for Alzheimer's disease in a memory clinic setting. , 2013, 9, P144-P145.		0
173	P1-149: CSF VILIP-1 AND YKL-40, NOVEL CANDIDATE BIOMARKERS TO DIAGNOSE, PREDICT, AND MONITOR ALZHEIMER'S DISEASE. , 2014, 10, P355-P355.		0